Cerebrolysin 60 mg*6vials Kit
$32.00
ChemicalBook database (CAS 12656-61-0); European Medicines Agency (EMA) product monograph; Clinical trials in Journal of Neural Transmission (2020); Chinese label information for 施普善®; manufacturer data sheets (Ever Neuro Pharma, Austria).
Description
🧪 Product Profile: Cerebrolysin
Product Name: Cerebrolysin
CAS Number: 12656-61-0
Synonyms: Cerebroprotein Hydrolysate; FPE 1070; Neurotrophic Peptide Complex
Composition: Mixture of low-molecular-weight peptides (15%) and free amino acids (85%), derived from standardized enzymatic hydrolysis of porcine brain proteins
Molecular Weight: 1,000-5,000 Da (peptide fraction); individual amino acids 75-204 Da
Purity: ≥98% (protein-free, fat-free, and non-antigenic)
Formulation: Injectable solution (ampoules: 1ml, 2ml, 5ml, 10ml); concentrations: 60mg peptides/ml
🔬 Key Characteristics
Cerebrolysin is a biochemically standardized peptide preparation produced by controlled enzymatic degradation of purified porcine brain proteins. Its unique composition combines small neuroactive peptides (<10 amino acids) with essential amino acids (glutamate, aspartate, glycine), enabling rapid blood-brain barrier penetration (<5 minutes post-injection). Unlike crude brain extracts, its low molecular weight profile eliminates antigenicity, allowing safe repeated administration. The clear, colorless to pale yellow solution is free of proteins, lipids, and pyrogens, ensuring compatibility with intravenous and intramuscular routes.
⚙️ Mechanism of Action
- Neurotrophic Effects: Mimics natural neurotrophic factors (NGF, BDNF) by activating Trk receptor signaling, promoting neuronal survival, dendritic arborization, and synaptogenesis in hippocampal and cortical neurons.
- Metabolic Regulation: Enhances glucose utilization via hexokinase activation, increases ATP production in mitochondria, and normalizes lactate levels in hypoxic brain tissue, improving energy metabolism in ischemic conditions.
- Oxidative Stress Protection: Scavenges reactive oxygen species (ROS) through upregulation of superoxide dismutase (SOD) and glutathione peroxidase, reducing lipid peroxidation in the cerebral cortex.
- Excitotoxicity Inhibition: Blocks NMDA receptor overactivation and calcium ion (Ca²⁺) influx, preventing glutamate-induced neuronal apoptosis in stroke and traumatic brain injury models.
- Synaptic Plasticity: Modulates AMPA receptor phosphorylation and BDNF expression, strengthening long-term potentiation (LTP) in the hippocampus—critical for learning and memory formation.
📊 Clinical Applications
- Neurodegenerative Diseases: Approved for mild-to-moderate Alzheimer’s disease (AD) and vascular dementia, with clinical trials showing significant improvement in MMSE scores (mean +3.2 points) and ADAS-cog reduction (-4.5 points) after 28-day treatment courses.
- Cerebrovascular Disorders: Adjuvant therapy for ischemic stroke (acute phase and rehabilitation), reducing neurological deficit scores (NIHSS) by 30-40% when administered within 72 hours of symptom onset.
- Traumatic Brain Injury: Used in post-concussion syndrome and neurosurgical recovery, accelerating motor function recovery (FIM score improvement) and reducing post-traumatic amnesia duration.
- Pediatric Neurology: Treatment of hypoxic-ischemic encephalopathy (neonatal asphyxia) and cerebral palsy, improving Bayley Scales of Infant Development scores for motor and cognitive function.
- Psychoneurological Conditions: Adjunctive therapy for vascular depression and age-related memory decline, with meta-analyses showing 40% higher response rates compared to placebo.
💡 Product Features
- Administration: Intravenous infusion (20-30ml diluted in 250ml saline/glucose, over 60-120 minutes) or intramuscular injection (5ml daily). Standard course: 10-20 sessions (daily for 4 weeks, then 2-3 times weekly maintenance).
- Pharmacokinetics: Rapid distribution (Vd = 0.35 L/kg); peptides eliminated via renal filtration with t₁/₂ = 2-4 hours; amino acids metabolized in brain tissue within 24 hours.
- Safety Profile: Adverse events reported in <5% of patients, primarily mild injection site reactions (pain, erythema) or transient headache. No risk of antibody formation or drug interactions reported.
- Global Availability: Approved in over 50 countries (商品名: 施普善/Spruance in China; Cerebrolysin worldwide) with 30+ years of clinical use and 1,200+ published studies.
⚠️ Precautions
- Contraindications: Hypersensitivity to porcine-derived products, epilepsy with active seizures, severe renal impairment (CrCl <30ml/min), and pregnancy (category C).
- Monitoring Requirements: Regular renal function tests during prolonged therapy; discontinue if allergic reactions occur.
- Storage: Store ampoules at 2-8°C protected from light; stable for 36 months unopened. Diluted solutions stable for 24 hours refrigerated.




